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ABSTRACT  
 
Objective: 
Neuroimaging studies show structural differences in both cortical and subcortical brain regions in 
children and adults with autism spectrum disorders (ASD), compared to controls. Findings are 
inconsistent, however, and it is unclear how differences develop across the lifespan. We aimed to 
investigate brain morphometry differences between participants with ASD and controls cross-
sectionally across the lifespan, in a large worldwide sample from the ENIGMA-ASD Working Group. 
 
Methods: 
The sample comprised 1571 patients with ASD and 1651 healthy controls from 49 participating sites 
(age range: 2-64 years). MRI scans were preprocessed at individual sites with a harmonized protocol 
based on validated, automated segmentation software. Mega-analyses were used to test for case-
control differences in subcortical volumes, cortical thickness and surface area. Development of brain 
morphometry over the lifespan was modeled using a fractional polynomial approach. 
 
Results: 
The case-control mega-analysis demonstrated that ASD was associated with smaller subcortical 
volumes of the pallidum, putamen, amygdala and nucleus accumbens (effect sizes d=0.11 to d=0.16), 
as well as increased cortical thickness in the frontal cortex and decreased thickness in the temporal 
cortex (effect sizes d=0.20 to d=-0.21). Analyses of age effects indicate that the development of 
cortical thickness is altered in ASD, with the largest differences occurring around adolescence. No age 
by ASD interactions were observed in the subcortical partitions.  
 
Conclusions: 
The ENIGMA-ASD working group provides the largest study of brain morphometry differences in ASD 
to date, using a well-established and validated publicly available analysis pipeline. ASD subjects 
showed altered morphometry in the cognitive and affective parts of the striatum, frontal cortex and 
temporal cortex. Complex developmental trajectories were observed for the different regions, with a 
developmental peak around adolescence. Our findings suggest an interplay in the abnormal 
development of the striatal, frontal and temporal regions in ASD across the lifespan.  
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Introduction 
 
Autism Spectrum Disorder (ASD) is a relatively common childhood onset neurodevelopmental 
disorder, affecting about 1.4% of the population (1–3). ASD is usually diagnosed before age 6, and 
often leads to lifelong problems in social adaptation and impaired functioning.  Although ASD is highly 
heritable and considered to be a brain-based disorder, the biological underpinnings of the disorder 
and its development over the lifespan remain largely unclear. 
Much research has focused on the role of anatomical brain abnormalities in ASD (4–7). Both larger (7) 
and smaller (8) volumes of striatal structures have been reported in ASD, as well as smaller 
hippocampal (9) and – in childhood – larger amygdala volumes (10). Increased intracranial volume 
(11), total grey matter and cortical thickness have also been reported in ASD (12), with more specific 
cortical effects observed mainly in the frontal (13) and temporal lobes (14). These structural 
abnormalities play a crucial role in current theories on the neurobiology of autism. Specifically, altered 
frontal and striatal volumes and disrupted fronto-striatal connectivity are key components in the 
executive function deficit theory of ASD (15–17). On the other hand, abnormal amygdala volume, 
specifically in childhood (18; 19), plays a central role in the social theories of ASD (10; 20; 21). 
However, existing neuroimaging studies report considerable heterogeneity in the direction and effect 
size of these morphometric brain differences (12; 22; 23), with a recent large scale study by Haar et 
al. even indicating overall increased grey/white matter measures, but very small local effects of ASD 
on brain morphometry (12).  This heterogeneity in the literature may be due to various factors. Firstly, 
variation in case-control differences of brain structures may be due to age differences between study 
samples. Prior research suggests altered patterns of cortical and subcortical development in ASD, 
generally reporting abnormally higher volumes in childhood followed by a more rapid volumetric 
decline during adolescence and adulthood (13; 24–26). Secondly, factors like sex, medication use, 
symptom severity and presence of comorbidities may also affect case-control differences in brain 
structures. Furthermore, methods based factors such as variation in data acquisition, processing and 
analysis protocols may influence the results reported across different studies. 
Several recent studies have used the anatomical differences in ASD as the basis for multivariate 
analyses with the ultimate goal of using these differences as a tool for categorizing ASD (12; 27; 28). 
These efforts, however, remain yet to be validated in clinical settings (29). The heterogeneity of 
anatomical differences in the various samples may also underlie the lack of consistent results in this 
line of research. 
The current study addresses several of these issues. Specifically, the current collaboration was 
established as part of ENIGMA, the world-wide imaging genetics consortium aimed at unifying 
analyses methods across a range of neuropsychiatric disorders. We use the ENIGMA processing and 
analysis pipelines to merge individual subject data from 49 existing ASD case-control cohorts (of which 
16 cohorts were collected previously as part of the ABIDE consortium (6), and 17 as part of ABIDE –II 
(30)) to determine whether and which changes in subcortical volumes as well as cortical thickness and 
surface area underlie the ASD phenotype across the lifespan. By unifying processing and analysis, we 
were able to eliminate a large part of the methodological noise between individual studies. 
Additionally, we were able to investigate directly the effects of sex, IQ and symptom severity across 
this extensive sample. Last but not least, studies employing small sample sizes are liable to 
overestimate effect sizes (31). With 43 of the 49 currently included cohorts employing sample sizes of 
less than 100 subjects, it is important to test whether results of small scale studies remain robust 
within this large cohort. 
 Based on existing literature, we expect subjects with ASD to show smaller subcortical volumes 
specifically in the putamen, caudate, but larger volumes in hippocampus and amygdala. We 
furthermore expect generally increased grey matter volumes and cortical thickness in subjects with 
ASD, specifically we expect increased thickness in frontal and temporal cortices (32).   Given the broad 
age range of the current sample, we also charted in detail the development of these morphological 
features over the lifespan in ASD, albeit based on cross-sectional data. Based on previous studies, we 
expect the largest effects of ASD during childhood with normalization of features over adolescence 
and adulthood (13; 24–26) 
  
Methods 
 
Contributing sites 
The ENIGMA-ASD working group is an open cohort, aimed at bringing together MRI data from a wide 
range of ASD studies. The working group was started in 2015, and remains open for any new groups 
working with ASD patients of any age. The working group implemented a data freeze to execute the 
current subcortical volume analyses in March 2017, at which point we included a total of 1571 patients 
with ASD and 1651 healthy controls from 49 participating research groups, spanning 13 countries. 
Both the ABIDE and ABIDE-2 consortia were included in the current cohort (6; 30). Demographic 
information for all participants may be found in Table 1 and Figure 1, details of the different 
contributing samples can be found in Supplementary Table 1.  All contributing sites had local ethical 
approval for the sharing of meta-analytic test statistics, 48 out of 49 sites had approval for sharing 
anonymized individual data. Even though we included samples from the entire ASD spectrum, the vast 
majority of the included individuals did not have an intellectual disability, hence the comparable IQ 
scores between patients and controls. 
 
(Insert Table 1 here) 
 
(Insert Figure 1 here) 
 
FreeSurfer segmentation 
Structural T1-weighted MRI scans acquired at different contributing sites were segmented using 
standardized and publically available ENIGMA imaging protocols 
(http://enigma.ini.usc.edu/protocols/imaging-protocols/). These automated protocols based on 
Freesurfer5.3 segmentations are fully validated, to allow maximal uniformity and comparability across 
sites. For each participant, left and right subcortical volumes, cortical thickness and cortical surface 
area measures were calculated. The mean of left and right volumes were used for most subsequent 
analyses. Standardized quality control depended on the automatic detection of segmentation outliers 
for each volume, followed by visual inspection of outlying volumes. Poorly segmented regions were 
removed from further analyses. Detailed information on the QC procedure can be found in the 
supplementary information. 
 
Case-control analyses 
The main aim of this study was to investigate differences in (sub)cortical morphometry related to ASD 
status. To accomplish this, individual segmentation subcortical volumes, cortical thickness and cortical 
surface area were merged for participants over all sites into one “mega-analysis”. The effect of 
diagnosis (patient/control) on each ROI was calculated using a linear mixed effects model (nlme 
package in R) including a polynomial fit for age, sex and IQ as fixed factors, and age*diagnosis and 
age*sex interactions. For subcortical volumes, total ICV was added as a fixed factor. Scan site was 
added as a random factor. P-values were corrected for multiple comparisons using the false discovery 
rate (FDR) adjustment. 
Several additional sensitivity analyses were performed to investigate how sex, IQ, medication use, 
comorbidities, ASD severity, hemisphere effects or total ICV differences might have influenced the 
main effect of ASD status on (sub)cortical measures. Age and sex information were available for all 
incorporated studies. For IQ, medication use, comorbidities and ASD severity, data were available for 
some samples (see supplement for the available data per site). Given the large variation in available 
detail on medication use and comorbidity assessment, these were included in the analyses as a 
dichotomous measure (current medication vs no medication use, current comorbidity vs no 
comorbidities). For ASD severity, the most ubiquitously available measure was the total ADOS_G score 
(33), which was used as an estimate of ASD severity. For a more detailed comparison to the Haar et 
al. (12) study, a permutation based post-hoc analysis was performed.  
To allow for comparisons across the different sites as well as to control for any unobserved effects 
that may influence the mega-analysis, we repeated the same analysis of the diagnosis effect in a more 
conservative meta-analysis, running a linear regression model for each site separately. The I2 statistic 
(34) was calculated to estimate the heterogeneity of the diagnostic effects across sites, indicating the 
percentage of variation across studies that is due to heterogeneity rather than chance.  
 
Age effects modeling 
Given the importance of developmental trajectories when estimating the effects of ASD, we used a 
fractional polynomial approach to estimate the optimal fit for development of the volume, thickness 
or surface area with age (mfp package in R) (35). For all ROIs that showed a significant effect of age or 
age*diagnosis interaction in the mega-analysis, the optimal model was estimated for ASD subjects and 
healthy controls using one- and two-term curvilinear models, choosing the best fitting model out of 
44 possible two-term models - with possible powers of -2, -1, -0.5, 0, 0.5, 1, 2 and 3 (these models also 
included sex, IQ, and scan-site as covariates). 
 
Power Calculation 
Using G*Power version 3.2.1, we calculated the minimal effect sizes observable given 1,571 
participants with ASD and 1,651 healthy controls. At a minimum desired power level of 0.8 and p-
value of 0.05 (two-tailed), we have power to observe effects of d>0. 108 (Cohen’s d).  
  
Results 
 
Case-control differences in subcortical and cortical partitions 
Both sex and IQ were not distributed equally between the subjects with ASD and healthy controls. 
There were proportionally more females in the control than ASD group (23.8%, as compared to 
14.25%; p<.001) and controls had a significantly higher mean IQ (111 vs 103, p<.001). Both sex and IQ 
were incorporated as covariates in the main mega-analysis to correct for these differences. Additional 
sensitivity analyses without correction for IQ as well as analyses with subgroups balanced on sex and 
IQ can be found in the supplementary information. The effects of medication use and associations 
with symptom severity were also investigated. 
The results of the subcortical mega-analysis are presented in Table 2 and Figure 1. Even though the 
hippocampus is technically a cortical area we have chosen to add hippocampal volume to the 
subcortical results, since it is segmented as a subcortical volume in Freesurfer. ASD was associated 
with significantly smaller mean volumes of the putamen (p<.001, d=-0.10), pallidum (p<.05, d=-0.08) 
amygdala (p<.05; d=-0.08) and nucleus accumbens (p<.001, d=-0.13), as well as larger mean volumes 
of the lateral ventricles (p<.001, d=0.11) and ICV (p<.001, d=0.13). Additional sensitivity analyses 
correcting the subcortical volumes for intracranial gray matter volume instead of total ICV are added 
to the supplementary materials. 
The effects of ASD diagnosis on cortical thickness are presented in Table 3. We observe significantly 
increased overall cortical thickness (p<.003, d=0.41) in subjects with ASD, as well as more specifically 
in 9 of the 34 cortical partitions, located in the middle and superior frontal, orbitofrontal, inferior 
frontal and posterior cingulate areas. Inversely, decreased cortical thickness was observed in subjects 
with ASD in 7 partitions, located in the temporal, entorhinal and parahippocampal areas (see Figure 
2). We also found increased overall grey matter volume (p<.052, d=0.23) among subjects with ASD. 
No effects of ASD diagnosis on cortical surface area were found.   
 
(Insert Figure 2 here) 
 
(Insert Table 2 here) 
 
Post hoc analyses per hemisphere indicated that for the lateral ventricles (left p<.004; right p<.006), 
putamen (p<.03, p<.05) and nucleus accumbens (p<.008; p<.02) both hemispheres contribute to the 
overall effect. For the hippocampus and amygdala only the right hemisphere showed a significant 
effect (p<.05; p<.03). Increased cortical thickness in subjects with ASD was observed in frontal cortex 
for both hemispheres, as well as decreased thickness in the temporal cortex. In the right hemisphere, 
significantly thicker cortex in ASD was furthermore observed in the cingulate cortex, and decreased 
thickness in the parietal cortex (see Supplementary Table 8). 
 
To investigate differential effects between sites, a meta-analysis was performed by treating every site 
independently and aggregating the results. The results from the case-control meta-analysis confirmed 
smaller pallidum (p<.04, d=-0.09), amygdala (p<.03, d=-0.09) and nucleus accumbens (p<.01, d=-0.1) 
volumes in ASD; as well as higher volumes of the lateral ventricles (p<.003, d=0.13) and ICV (p<.016, 
d=0.06). The meta-analysis also showed increased cortical thickness in subjects with ASD in 3 out of 
11 of the frontal partitions, and decreased thickness in 8 out of 9 temporal partitions, as well as in the 
supramarginal gyrus (see Supplementary Table 2). Overall, the meta-analysis showed smaller effect 
sizes and higher standard error of effect sizes than the mega-analysis. The I2 test indicates moderate 
to high heterogeneity across sites for all effect sizes (I2=15.19–64.63). Individual test statistics for the 
case-control comparison per site are listed in the supplementary materials (see Supplementary Table 
12).  
 
Age effects 
Main linear effects of age were observed for all subcortical volumes (see Table 2). However, no 
interaction effects between diagnosis and age were found. We calculated fractional polynomial fits 
for the age effect for all the above mentioned ROIs, estimating the polynomial fit for these volumes 
(see Figure 3 and Supplementary Table 11). The fractional polynomial approach indicates that the 
optimal model for the age effect in all subcortical volumes contains the powers of 0.5 and 2 (see Figure 
2). These results indicate that the developmental curves of the subjects with ASD and healthy controls 
follow similar trajectories over time, which confirms the observed lack of detectable age by diagnosis 
interactions. 
Main linear effects of age on cortical thickness were observed in 30 out of 34 partitions, all of them 
showing a negative relation between age and thickness (see Table 1). The 4 partitions not showing a 
significant effect were all overlapping with the partitions showing a negative relation between 
thickness and ASD diagnosis (temporal, entorhinal and parahippocampal areas). A quadratic effect of 
age was observed in the insula. Age by diagnosis interactions were further observed in 24 of the 
partitions that also showed a linear age effect. Fractional polynomial plots were calculated for these 
partitions as well, showing complex developmental curves including both quadratic and cubic effects 
across the partitions (see Figure 3). These visualizations indicated that subjects with ASD show a peak 
in cortical thickness differences around adolescence, with both the greater thickness in the frontal 
cortex and lesser thickness in the temporal cortex peaking around this age.  
 
(insert Figure 3 here) 
 
Sex and IQ effects 
The mega-analysis shows significant effects of sex on ICV, lateral ventricles, thalamus, caudate, 
putamen, amygdala and nucleus accumbens volumes, indicating larger volumes in males than females. 
No interactions between diagnosis and sex were observed. Effects of IQ on brain volumes were 
observed for the putamen, hippocampus, amygdala and nucleus accumbens volumes, with larger 
volumes associated with a higher IQ (see Table 2). The three-way interaction of diagnosis, age and sex 
rendered no significant results. 
Effects of sex on cortical thickness were observed in transverse temporal, caudal-middle frontal and 
superior frontal partitions, all of them indicating thicker cortex in males. Subjects with a higher IQ 
showed greater cortical thickness in precentral and rostral anterior cingulate partitions, and lower 
thickness in medial orbitofrontal and caudal anterior cingulate partitions.  
 
Medication, comorbidity and symptom severity effects 
Within subjects with ASD, further mega-analyses were performed to test for any effects of medication 
use, comorbidities and ASD symptom severity on subcortical volumes (see supplementary materials). 
Neither medication use nor the presence of comorbidities significantly influenced subcortical volumes 
within this sample. Cortical thickness was associated with medication use only in the inferior-temporal 
partition (d=-0.47, p<.002), but not with comorbidity.  ASD symptom severity analyses showed that 
higher ADOS scores were associated with larger ICV and lateral ventricles, and lower volumes in 
putamen, nucleus accumbens, thalamus, amygdala and hippocampus (see Supplementary Table 9).  
Greater thickness in the frontal areas and lower thickness in the temporal areas was associated with 
higher ADOS scores.  Interestingly, higher ADOS scores were additionally associated with increased 
thickness in cingulate, parietal and occipital regions, while lower cortical thickness was associated with 
higher ADOS scores in the insula.  
 
 
   
Discussion 
 
We investigated subcortical brain volumes, cortical thickness and surface area in the largest sample 
to date of participants with ASD and typically developing controls in a wide age range. ASD was found 
to be associated with significantly smaller volumes of putamen, pallidum and nucleus accumbens, but 
larger volumes of the lateral ventricles. Subjects with ASD also showed generally larger ICV, total GM 
and total cortical thickness, but no differences in surface area. Our analyses indicate a split in the 
direction of cortical thickness effects between the frontal and temporal cortices, where subjects with 
ASD showed increased cortical thickness in the frontal cortex, but decreased thickness in the temporal 
cortex. The effect sizes of these cortical and subcortical group differences ranged from d=-0.21 to 0.20, 
indicating small to moderate effects and significant overlap in the distribution of brain morphometry 
measures between participants with ASD and healthy controls, in line with effect sizes found in the 
ENIGMA-ADHD, Schizophrenia and Bipolar disorder working group findings (36–38). 
 
Increased cortical thickness in general, as well as increased lateral ventricle volumes, are all in line 
with previous results found in the meta-analysis by Haar et al. (12), although they do not find any 
alterations in the basal ganglia volumes or frontal cortical thickness. Decreased temporal cortical 
thickness and increased frontal thickness however were observed in another recent large scale meta-
analysis on brain morphometry in ASD (39).  Our sensitivity analyses based on the permutation testing 
used in the Haar et al. (12) study indicate that the discrepancies with the current results can mainly 
be attributed to differences in sample size, as we replicate prior results using the permutation method 
on our larger cohort sample. This comparison further indicates the necessity of large scale cohort 
studies, and stresses the caution needed when interpreting effects with these limited effect sizes. 
 
The involvement of pallidum, putamen and nucleus accumbens indicates an important role for the 
socio-motivational and cognitive and motor systems of the striatum in the neurobiology of ASD (40). 
Taken together with the increased cortical thickness in the frontal cortical regions, which are mainly 
involved in cognitive control, these findings are in line with prior studies relating aberrant frontal-
striatal connectivity to the repetitive behavior and executive functioning deficits observed in ASD (6; 
14; 17; 41). Nucleus accumbens deficits have additionally been suggested to support the theory of 
social reward based differences underlying part of the behavioral phenotype in ASD (15). In contrast 
to some earlier findings (19), but in line with others (10), we also find a slightly smaller amygdala 
volume in ASD. Further research is necessary to investigate whether nucleus accumbens and amygdala 
volume changes are related to social and reward processes in ASD. Decreased thickness in the 
temporal cortex in ASD may be further related to both social (42) and language deficits in ASD (43). 
Our post-hoc analyses on ASD severity further indicate that cortical and subcortical morphometry is 
related to ASD severity, following the same direction as the group effect, indicating that these 
alterations indeed serve a functional role in the ASD etiology.  
 
The age distribution in the current sample ranged from 2 to 64 years, providing an unprecedented 
cross-sectional view of the development of brain morphometry in ASD and healthy controls over the 
lifespan. Our subcortical results indicate complex - linear and quadratic - age effects in thalamus, 
hippocampus, amygdala, nucleus accumbens and lateral ventricles. The fractional polynomial fits for 
these volumes indicate that over all groups the subcortical volumes follow a quadratic growth model 
with a distinct peak around puberty, which is in line with previous literature on development of these 
regions (44). As opposed to some prior studies and reviews (e.g. (26)), no evidence was found for 
age*diagnosis interaction effects in any of the investigated subcortical volumes (45). Cortical 
thickness, on the other hand, showed large scale effects of both age and age*diagnosis interaction. 
We observed a general declining cortical thickness over age, in line with previous literature (13; 32). 
However, as compared to controls, subjects with ASD in general showed strongest group differences 
during childhood and adolescence, with normalized or even reversed thickness results in adulthood. 
Interestingly, this was observed both for the increased thickness in ASD in the frontal areas as well as 
the decreased thickness in the temporal lobe. These results indicate a complex maturation pattern for 
the subcortical, frontal and temporal structures in ASD, peaking around adolescence. Specifically, the 
balance of frontal, temporal and striatal maturation may prove a valuable marker for the development 
of ASD symptoms and treatment response, though further longitudinal studies are required to verify 
the predictive validity of these morphometric measures. 
 
Our findings also replicate previously reported main effects of sex (46) and IQ (47) on brain volumes, 
with generally larger subcortical volumes and increased thickness found in males and in participants 
with a higher IQ. The mega-analytic approach can statistically correct for differences in sex and IQ 
between participating sites, removing some of the outcome variance associated with different 
distributions of these factors between sites. We observed that males have, on average, larger basal 
ganglia volumes and increased cortical thickness, but patient groups had a larger proportion of males, 
indicating that sex could not have confounded the ASD effect. Although we find no evidence of sex by 
diagnosis interaction, the increased volumes and thickness in both males and females with ASD could 
be taken as evidence for the ‘extreme male brain’ hypothesis, (48), though this study was not optimally 
designed to validate this hypothesis, while other recent large scale studies have found considerable 
evidence for gender effects in brain morphometry in ASD (49). We aim to replicate the analysis by 
Ecker et. al. in a future publication of the ENIGMA-ASD cohort. Neither medication use nor 
comorbidity had any large scale influence on brain morphometry in ASD. Within the ASD sample, 
overall effects of symptom severity were largely consistent with the direction of the between-group 
effects. This supports the inference that the observed differences in morphometry are indeed related 
to the phenotypic expression of ASD in this cohort. 
 
Since individual participant data was available for almost the entire sample, we could compare meta- 
and mega-analytic approaches in this dataset. The main difference between these approaches is that 
in a meta-analysis, within and between group variance is estimated for each separate site, while for 
the mega-analysis, variance is estimated within-group. Our results indicate that the meta-analysis is 
generally less sensitive to group differences, with smaller effect sizes and higher standard errors found 
in the meta-analysis. The meta-analysis also allowed us to investigate the effects of ASD on brain 
morphometry per site (as seen in the supplementary results). This analysis indicates significant 
heterogeneity in the direction and size of the effects between participating sites. The heterogeneity 
of effect sizes as expressed with the i2 measure was moderate to high for all volume differences found. 
This heterogeneity is very important to take into account when interpreting single sample studies. 
Even though all the data in the current study were processed using the same analysis and QC pipeline, 
and were corrected for effects of age, sex and IQ identically across sites, we still find significant 
differences in the estimated main effects between sites. Some of these differences may be due to 
random sampling differences of the ASD population, in particular within the smaller samples. 
However, this is less likely to be the case in larger samples employing hundreds of subjects. 
Alternatively, the within-group heterogeneity might be indicative of different biological mechanisms 
or subtypes underlying ASD, and may therefore be informative for further classification studies. In any 
case, the existence of this heterogeneity underlines the importance of large scale studies such as 
ENIGMA to develop reliable benchmarks for the different major psychiatric disorders. The 
establishment of these benchmarks allows us to more accurately tackle the heterogeneity due to 
measurement differences and biological differences in neurodevelopmental studies. Planned 
multivariate factor analyses and subtyping analyses may additionally provide further insight into 
different biological mechanisms in ASD.  
 
One of the main goals of the ENIGMA consortium is to unify analysis methods not only over samples, 
but also over different disorders. The recent publication of the ENIGMA-ADHD working group is based 
on the same analysis pipeline and mega-analysis as the current study, using a similarly sized sample of 
participants with ADHD and controls (38). The ENIGMA-ASD and ADHD results suggest similar decrease 
of volumes in the putamen, amygdala and nucleus accumbens, whereas differences are found in the 
pallidum volume in ASD but not ADHD. Additionally, age analyses of subcortical volumes using 
fractional polynomials suggest different patterns of neural development in ASD and ADHD. Whereas 
subjects with ASD show similar volume growth curves as controls, subjects with ADHD showed a 
significant diagnosis by age interaction, with different developmental models most clearly seen in 
nucleus accumbens and putamen volumes for subjects with ADHD (38). These partly overlapping 
striatal volume differences offer a fascinating starting point for further investigation of the shared and 
unique neurobiological underpinnings of both ADHD and ASD, as direct comparisons between these 
two cohorts have not yet been completed at the time of writing. 
 
Some limitations should be considered when interpreting these findings. Primarily, our different 
participating sites used different scanners and acquisition protocols. Though we have controlled for 
the effects of scan site in our models, we cannot fully exclude potential influence of these 
measurement protocols on the data. We were also unable to obtain longitudinal data for the current 
samples, which prohibits a within-subject analysis of brain development in ASD. Future large scale 
efforts should in our opinion be aimed at also standardizing acquisition protocols and long term follow 
ups.  
 
To conclude, this study showed the abnormal development of cortical thickness and subcortical 
volumes in ASD in the largest sample to date, as obtained by the ENIGMA-ASD working group. We 
observed smaller volumes of putamen, amygdala, nucleus accumbens and pallidum, increased frontal 
cortical thickness and decreased temporal cortical thickness in ASD compared to controls. Our age 
analyses, show that subcortical differences in ASD remain relatively stable over the lifespan, whilst 
cortical alterations in ASD show a peak in childhood and early adolescence, and taper off over 
adulthood. Future functional activation and resting-state connectivity studies will want to take into 
account these differences in maturation, and focus on unraveling how the balance between frontal, 
temporal and subcortical alterations influences the expression of the ASD phenotype across the 
lifespan. No differences in the development of brain morphometry was observed between males and 
females with ASD. 
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Tables: 
 Controls ASD group difference 
N 1651 1571   
Age (mean) 15.83 15.41 - 
Age (SD) 8.41 8.64 - 
Age (range) 2-56 2-64 - 
Females (N) 393 224 Controls > ASD*** 
Females (%) 23.8 14.25 Controls > ASD*** 
IQ (Mean) 111 103 Controls > ASD*** 
IQ (Range) 80-149 65-123  
Medication use (N) 0 233  
Comorbidities (N) 0 148  
 
Table 1. Demographics of all participants. *** p-value <.001. Medication use indicates any type of 
current medication use, regardless of duration. Comorbidities indicate any type of current comorbid 
psychiatric disorders.   
  
Subcortical 
N 
controls 
N 
patients 
Diagnosi
s 
(Cohen’s 
d) 
Diagnosi
s (p-FDR) 
Age 
(Cohen’
s d) 
Age (p-
FDR) 
Age * 
Diagnosi
s (p-FDR) 
Sex 
(Cohen’
s d) 
Sex (p-
FDR) 
IQ 
(Cohen's
-d) 
IQ (p-
FDR) 
Lateral Ventricles 1569 1482 0.11 0.01 0.16 0.001 0.529 -0.096 0.064 0.17 0.050 
Thalamus 1597 1494 0.00 0.989 0.07 0.042 0.654 -0.111 0.034 0.01 0.110 
Caudate 1604 1517 -0.05 0.206 -0.19 0.001 0.230 -0.154 0.003 0.00 0.150 
Putamen 1600 1518 -0.10 0.013 -0.12 0.001 0.882 -0.218 <0.001 0.00 0.140 
Pallidum 1596 1509 -0.08 0.046 -0.26 0.001 0.261 0.01 0.839 0.00 0.140 
Hippocampus 1595 1507 -0.05 0.222 0.14 0.001 0.521 -0.053 0.310 0.02 0.100 
Amygdala 1601 1508 -0.08 0.046 0.13 0.001 0.230 -0.163 0.002 0.01 0.110 
Nucleus accumbens 1596 1518 -0.13 0.002 -0.19 0.001 0.230 -0.218 <0.001 0.13 0.060 
ICV 1606 1522 0.13 0.009 0.14 0.001 0.261 -0.239 <0.001 0.02 0.100 
Frontal                      
Superior Frontal 1574 1657 0.17 0.0000 -0.30 <.0001 0.000 0.08 0.0386 -0.03 0.7312 
Rostral Middle 
Frontal 1572 1658 0.20 0.0000 -0.39 <.0001 0.000 0.03 0.3790 -0.02 0.8178 
Caudal Middle 
Frontal 1574 1656 0.08 0.0567 -0.24 <.0001 0.000 0.08 0.0253 0.05 0.3965 
Pars Triangularis 1572 1653 0.11 0.0056 -0.31 <.0001 0.000 0.03 0.3418 -0.01 0.8178 
Pars Orbitalis 1573 1656 0.12 0.0023 -0.28 <.0001 0.000 0.03 0.4900 -0.07 0.3189 
Pars Opercularis 1572 1654 0.01 0.7333 -0.25 <.0001 0.002 0.00 0.9297 0.00 0.9818 
Medial Orbitofrontal 1572 1656 0.15 0.0003 -0.37 <.0001 0.000 -0.03 0.4060 -0.09 0.1432 
Lateral Orbitofrontal 1574 1655 0.05 0.2941 -0.32 <.0001 0.000 -0.03 0.3670 -0.02 0.8050 
Precentral 1569 1655 -0.06 0.1319 -0.10 0.006 0.544 0.04 0.2386 0.12 0.0298 
Paracentral 1574 1653 -0.01 0.7333 -0.29 <.0001 0.000 0.02 0.4919 0.06 0.3621 
Frontal Pole 1568 1655 0.10 0.0109 -0.25 <.0001 0.000 -0.02 0.5670 -0.02 0.8050 
Insula                      
Insula 1567 1651 -0.07 0.1133 -0.13 0.0007 0.454 -0.05 0.1950 -0.02 0.8178 
Cingulate                       
Rostral Anterior 
(Frontal) 1569 1652 0.02 0.5851 -0.20 <.0001 0.008 0.02 0.5408 -0.08 0.2284 
Caudal Anterior 
(Frontal) 1566 1651 0.03 0.5226 -0.16 <.0001 0.012 0.05 0.1972 -0.08 0.2284 
Posterior (Parietal) 1568 1657 0.13 0.0021 -0.22 <.0001 0.002 0.02 0.6343 -0.06 0.3754 
Isthmus (Parietal) 1572 1650 0.08 0.0436 -0.21 <.0001 0.001 -0.02 0.5424 -0.02 0.7873 
Parietal                      
Superior Parietal 1572 1654 -0.01 0.8190 -0.34 <.0001 0.000 0.06 0.1071 -0.01 0.8460 
Inferior Parietal 1572 1657 0.02 0.6392 -0.32 <.0001 0.000 0.01 0.7128 -0.02 0.8050 
Supramarginal 1572 1652 -0.07 0.0785 -0.27 <.0001 0.000 0.00 0.9924 0.03 0.7258 
Postcentral 1569 1655 -0.03 0.5226 -0.25 <.0001 0.000 0.03 0.4667 0.02 0.7873 
Precuneus 1573 1658 0.03 0.5261 -0.34 <.0001 0.000 0.04 0.2871 -0.06 0.3621 
Temporal                      
Superior temporal 1569 1652 -0.08 0.0623 -0.04 0.3132 0.387 0.00 0.9417 0.05 0.3965 
Middle temporal 1570 1653 -0.10 0.0141 -0.14 0.0002 0.150 0.02 0.5395 0.07 0.3189 
Inferior temporal 1571 1655 -0.14 0.0008 -0.15 <.0001 0.044 -0.05 0.1544 -0.05 0.4532 
Banks of the Superior 
Temporal Sulcus 1562 1647 -0.03 0.5226 -0.15 <.0001 0.098 -0.02 0.5548 0.03 0.7873 
Fusiform 1570 1655 -0.19 0.0000 -0.17 <.0001 0.024 -0.06 0.0967 -0.01 0.9140 
Transverse Temporal 1574 1655 -0.12 0.0026 -0.16 <.0001 0.039 0.09 0.0100 0.05 0.3965 
Entorhinal 1559 1641 -0.21 0.0000 0.00 0.9465 0.683 -0.01 0.8227 0.05 0.4532 
Temporal Pole 1565 1648 -0.13 0.0013 0.03 0.4236 0.481 -0.03 0.3445 0.03 0.7312 
Parahippocampal 1569 1653 -0.10 0.0144 -0.06 0.1230 0.556 0.05 0.1567 0.05 0.4532 
Occipital                      
Lateral Occipital 1569 1652 -0.05 0.2023 -0.21 <.0001 0.000 -0.02 0.5264 -0.02 0.7873 
Lingual 1572 1655 -0.04 0.4167 -0.24 <.0001 0.000 -0.03 0.4777 -0.01 0.8826 
Cuneus 1571 1651 0.07 0.0858 -0.27 <.0001 0.000 0.01 0.7860 -0.07 0.2784 
Pericalcarine 1571 1648 0.00 0.9335 -0.11 0.0029 0.150 0.05 0.1596 0.00 0.9869 
  
Table 2. Mega-analysis ASD v Control comparison model outcomes, including polynomial effects of age and IQ, as well as fixed effects for sex and a random 
effect for scan-site in the main regression model. All subcortical volumes are corrected for total ICV. All cortical thickness values are corrected for mean 
cortical thickness. Bold values indicate significant effects (p-values are FDR corrected). No significant effects on cortical surface area were observed. For the 
effect of Age, positive d-values indicate increasing volumes with higher age. For the effect of Sex, negative d-values indicate larger values in males. For the 
effect of IQ, positive d-values indicate a higher volume associated with higher IQ.  
 
 
Figures: 
 
 
 
Figure 1. Distributions of Age and IQ within the full sample. Blue bars represent frequencies within healthy 
controls, red bars in subjects with ASD. Purple bars indicate the overlap between the distributions.  
 
 
Figure 2. Mega-analysis of ASD vs Control comparison, visualizing effect sizes for all subcortical and cortical 
partitions. (A/B) show the medial and lateral view of the striatum. (C/D) show the medial and lateral view of 
cortical thickness.  Yellow/red hues indicate higher d-values, corresponding to larger volumes in patients with 
ASD. Blue hues indicate lower volumes in subjects with ASD. Images are in MNI-152 space.  
 
 
 Figure 3. Fractional polynomial best model fits for age for frontal cortical thickness (A), temporal cortical thickness (B), subcortical volumes (C) with significant diagnosis and 
age and/or age*diagnosis effects, as well as total ICV and total cortical thickness (D). . Separate fits shown for both subjects with ASD and healthy Controls. 
  
 
